Marlise R. Luskin

Dana-Farber Cancer Institute — United States

Medicine · Health Sciences

29h-index4.0kcitations423works1.92yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Acute Myeloid Leukemia Research(171), Acute Lymphoblastic Leukemia research(108), Chronic Myeloid Leukemia Treatments(104), Myeloproliferative Neoplasms: Diagnosis and Treatment(94), Drug Transport and Resistance Mechanisms(37)

Publications423 total

Mutant SRSF2-associated impaired erythropoiesis is defined by increased mTORC1 signaling due to FYN missplicing
Leukemia·2026
Risk stratification of patients with TP53-mutated myeloproliferative neoplasms
Leukemia·2026
Blinatumomab Nonresponse Correlates with Poor Survival After Brexucabtagene
Blood·2026
Patient Characteristics, Toxicity, and Response after Real World Administration of Obecabtagene Autoleucel and Brexucabtagene Autoleucel for Relapsed Acute Lymphoblastic Leukemia: A Rocca Analysis
Transplantation and Cellular Therapy·2026
Hypomethylating agents plus venetoclax versus intensive chemotherapy in acute myeloid leukemia with chromosome 5 and 7 abnormalities
Haematologica·2026Open Access
Baseline IPSS-M vs Pretransplant Risk Downstaging as Prognostic Determinants in MDS Undergoing Allogeneic Transplantation
Blood Advances·2026Open Access
Stratifying Survival: The Role of Social Determinants of Health on AML Outcomes by ELN 2022 Criteria
Blood Advances·2026Open Access
Comparative Effectiveness of HMA with Venetoclax Versus Intensive Chemotherapy in AML with Very-High-Risk Cytogenetics
Blood Neoplasia·2026Open Access
401. Host, treatment, and disease-related risk factors for invasive fungal disease in 549 patients with newly diagnosed high-risk myeloid malignancies treated with intensive induction chemotherapy
Open Forum Infectious Diseases·2026Open Access
Real-world toxicity of brexucabtagene autoleucel in adults with relapsed/refractory B-cell acute lymphoblastic leukemia
Blood Immunology & Cellular Therapy·2025Open Access
Figure S4 from Targeting MET and FGFR in Relapsed or Refractory Acute Myeloid Leukemia: Preclinical and Clinical Findings, and Signal Transduction Correlates
2025Open Access
Figure S2 from Targeting MET and FGFR in Relapsed or Refractory Acute Myeloid Leukemia: Preclinical and Clinical Findings, and Signal Transduction Correlates
2025Open Access
Table S2 from Targeting MET and FGFR in Relapsed or Refractory Acute Myeloid Leukemia: Preclinical and Clinical Findings, and Signal Transduction Correlates
2025Open Access
Table S3 from Targeting MET and FGFR in Relapsed or Refractory Acute Myeloid Leukemia: Preclinical and Clinical Findings, and Signal Transduction Correlates
2025Open Access
Figure S1 from Targeting MET and FGFR in Relapsed or Refractory Acute Myeloid Leukemia: Preclinical and Clinical Findings, and Signal Transduction Correlates
2025Open Access
Figure S6 from Targeting MET and FGFR in Relapsed or Refractory Acute Myeloid Leukemia: Preclinical and Clinical Findings, and Signal Transduction Correlates
2025Open Access
Figure S5 from Targeting MET and FGFR in Relapsed or Refractory Acute Myeloid Leukemia: Preclinical and Clinical Findings, and Signal Transduction Correlates
2025Open Access
Figure S3 from Targeting MET and FGFR in Relapsed or Refractory Acute Myeloid Leukemia: Preclinical and Clinical Findings, and Signal Transduction Correlates
2025Open Access
Table S1 from Targeting MET and FGFR in Relapsed or Refractory Acute Myeloid Leukemia: Preclinical and Clinical Findings, and Signal Transduction Correlates
2025Open Access
Supplementary Protocol from A Phase Ib/II Study of Ivosidenib with Venetoclax ± Azacitidine in <i>IDH1</i>-Mutated Myeloid Malignancies
2025Open Access
page 1 of 22Next →

Frequent Co-authors

Daniel J. DeAngelo(22), Richard M. Stone(21), Jacqueline S. Garcia(12), Donna Neuberg(10), Martha Wadleigh(10), Eric S. Winer(9), Andrew M. Brunner(9), Shai Shimony(7), R. Coleman Lindsley(6), Yael Flamand(6), Robert J. Soiffer(5), Ran Reshef(5), David Porter(5), Ilene Galinsky(5), Selina M. Luger(5), Lachelle D. Weeks(4), Edward A. Stadtmauer(4), Gabriela Hobbs(4), Marina Konopleva(4), Mark J. Levis(4)